Chronic Lymphocytic Leukemia | Specialty

CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

March 31st 2018

Approaching Therapy for Relapsed/Refractory CLL

March 31st 2018

Novel Frontline Combinations With Ibrutinib in CLL

March 31st 2018

Ibrutinib's Value as Frontline Therapy in CLL

March 31st 2018

Sequencing Strategies in Frontline CLL

March 31st 2018

Selecting the Optimal Frontline Therapy in CLL

March 31st 2018

Evolution of Biological Understandings in CLL

March 31st 2018

Impact of Prognostic Factors on Clinical Decisions in CLL

March 31st 2018

Other Prognostic Factors in Chronic Lymphocytic Leukemia

March 31st 2018

TP53 and Deletion 17p as Prognostic Factors in CLL

March 31st 2018

Dr. Skarbnik on the Role of Chemotherapy in CLL

March 30th 2018

Alan Skarbnik, MD, staff physician, Department of Bone Marrow Transplantation and Department of Lymphoma, John Theurer Cancer Center, discusses the use of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

Dr. Barrientos Discusses Acalabrutinib in CLL

March 29th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the role of acalabrutinib (Calquence) for patients with chronic lymphocytic leukemia (CLL).

Dr. Kay Discusses the Role of Ibrutinib in CLL

March 26th 2018

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Byrd Discusses the Future Treatment of CLL

March 23rd 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the future treatment of patients with chronic lymphocytic leukemia (CLL).

Venetoclax/Rituximab Positive PFS Data Published in NEJM

March 22nd 2018

The regimen of venetoclax (Venclexta) plus rituximab (Rituxan) lowered the risk of disease progression or death by 83% versus bendamustine (Treanda) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

CLL Expert Explains Latest Treatment Developments in the Field

March 21st 2018

Neil E. Kay, MD, discusses the available options and sequencing challenges for patients with relapsed/refractory chronic lymphocytic leukemia, as well as next steps for advancing outcomes for this patient population.

Dr. Logan Discusses Acalabrutinib in CLL

March 19th 2018

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses acalabrutinib (Calquence) in chronic lymphocytic leukemia.

Ibrutinib, Venetoclax, and Obinutuzumab Triplet Safe, Effective as Initial CLL Therapy

March 16th 2018

Kerry A. Rogers, MD, discusses the promise of the obinutuzumab, ibrutinib, and venetoclax triplet as a first-line treatment for patients with chronic lymphocytic leukemia.

Dr. Barrientos on the Impact of Combinations in CLL

March 15th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of combinations in the treatment of chronic lymphocytic leukemia.

Dr. Kay Discusses the Role of Acalabrutinib in CLL

March 10th 2018

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia.